CL2022003141A1 - Terapia de combinación para amiloidosis de la ttr - Google Patents
Terapia de combinación para amiloidosis de la ttrInfo
- Publication number
- CL2022003141A1 CL2022003141A1 CL2022003141A CL2022003141A CL2022003141A1 CL 2022003141 A1 CL2022003141 A1 CL 2022003141A1 CL 2022003141 A CL2022003141 A CL 2022003141A CL 2022003141 A CL2022003141 A CL 2022003141A CL 2022003141 A1 CL2022003141 A1 CL 2022003141A1
- Authority
- CL
- Chile
- Prior art keywords
- ttr
- combination therapy
- ttr amyloidosis
- attr
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL2025001129A CL2025001129A1 (es) | 2020-05-12 | 2025-04-14 | Anticuerpo anti-ttr; y su uso para tratar amiloidosis de transtiretina. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20174177 | 2020-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003141A1 true CL2022003141A1 (es) | 2023-07-21 |
Family
ID=70682637
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003141A CL2022003141A1 (es) | 2020-05-12 | 2022-11-10 | Terapia de combinación para amiloidosis de la ttr |
| CL2025001129A CL2025001129A1 (es) | 2020-05-12 | 2025-04-14 | Anticuerpo anti-ttr; y su uso para tratar amiloidosis de transtiretina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025001129A CL2025001129A1 (es) | 2020-05-12 | 2025-04-14 | Anticuerpo anti-ttr; y su uso para tratar amiloidosis de transtiretina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230183329A1 (https=) |
| EP (1) | EP4149972A1 (https=) |
| JP (1) | JP7834032B2 (https=) |
| KR (1) | KR20230009950A (https=) |
| CN (1) | CN115551886A (https=) |
| AU (1) | AU2021272369A1 (https=) |
| BR (1) | BR112022023031A2 (https=) |
| CA (1) | CA3172824A1 (https=) |
| CL (2) | CL2022003141A1 (https=) |
| CO (1) | CO2022017877A2 (https=) |
| IL (1) | IL298135A (https=) |
| MX (1) | MX2022014223A (https=) |
| WO (1) | WO2021228987A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023099788A1 (en) * | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| AU2023382527A1 (en) * | 2022-11-15 | 2025-06-26 | Alexion Pharmaceuticals, Inc. | Methods for treating or preventing transthyretin-mediated amyloidosis |
| WO2024240562A1 (en) | 2023-05-19 | 2024-11-28 | Neurimmune Ag | Novel immunotherapy for musculoskeletal disorders and conditions |
| WO2025104243A1 (en) | 2023-11-15 | 2025-05-22 | Neurimmune Ag | Anti-transthyretin antibody, compositions comprising said antibody and methods for treating or preventing transthyretin-mediated amyloidosis |
| WO2025238147A1 (en) * | 2024-05-15 | 2025-11-20 | Neurimmune Ag | Maintenance treatment of cardiac ttr amyloidosis using anti-transthyretin antibodies |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9283271B2 (en) | 2010-12-17 | 2016-03-15 | Neurimmune Holding Ag | Human anti-SOD1 antibodies |
| US9169214B2 (en) | 2012-12-21 | 2015-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions |
| US10344080B2 (en) * | 2013-12-20 | 2019-07-09 | Neurimmune Holding Ag | Antibody-based therapy of transthyretin (TTR) amyloidosis and human-derived antibodies therefor |
| EP3101131B1 (en) | 2014-01-29 | 2020-08-19 | KM Biologics Co., Ltd. | Anti-transthyretin humanized antibody |
| EP3981874A1 (en) | 2014-01-29 | 2022-04-13 | KM Biologics Co., Ltd. | Anti-transthyretin human antibody |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| WO2018007923A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7017013B2 (ja) | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| CU24731B1 (es) * | 2017-10-06 | 2025-01-15 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina |
| CU20200042A7 (es) * | 2017-11-29 | 2021-03-11 | Prothena Biosciences Ltd | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina |
| US20210400932A1 (en) | 2018-11-09 | 2021-12-30 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
-
2021
- 2021-05-12 CN CN202180034796.0A patent/CN115551886A/zh active Pending
- 2021-05-12 AU AU2021272369A patent/AU2021272369A1/en active Pending
- 2021-05-12 MX MX2022014223A patent/MX2022014223A/es unknown
- 2021-05-12 WO PCT/EP2021/062706 patent/WO2021228987A1/en not_active Ceased
- 2021-05-12 JP JP2022568518A patent/JP7834032B2/ja active Active
- 2021-05-12 CA CA3172824A patent/CA3172824A1/en active Pending
- 2021-05-12 BR BR112022023031A patent/BR112022023031A2/pt unknown
- 2021-05-12 US US17/924,496 patent/US20230183329A1/en active Pending
- 2021-05-12 EP EP21724330.2A patent/EP4149972A1/en active Pending
- 2021-05-12 IL IL298135A patent/IL298135A/en unknown
- 2021-05-12 KR KR1020227043263A patent/KR20230009950A/ko active Pending
-
2022
- 2022-11-10 CL CL2022003141A patent/CL2022003141A1/es unknown
- 2022-12-09 CO CONC2022/0017877A patent/CO2022017877A2/es unknown
-
2025
- 2025-04-14 CL CL2025001129A patent/CL2025001129A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021228987A1 (en) | 2021-11-18 |
| EP4149972A1 (en) | 2023-03-22 |
| CL2025001129A1 (es) | 2025-11-28 |
| US20230183329A1 (en) | 2023-06-15 |
| AU2021272369A1 (en) | 2023-01-19 |
| MX2022014223A (es) | 2023-04-14 |
| CO2022017877A2 (es) | 2023-02-27 |
| JP7834032B2 (ja) | 2026-03-23 |
| KR20230009950A (ko) | 2023-01-17 |
| IL298135A (en) | 2023-01-01 |
| JP2023525790A (ja) | 2023-06-19 |
| BR112022023031A2 (pt) | 2022-12-20 |
| CA3172824A1 (en) | 2021-11-18 |
| CN115551886A (zh) | 2022-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022017877A2 (es) | Terapia de combinación para amiloidosis de la ttr | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| MX2024002561A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de tead y usos de las mismas para el tratamiento de canceres. | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| CO2023001561A2 (es) | Combinaciones para el tratamiento de cáncer | |
| CO2021004681A2 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| CL2022003511A1 (es) | Inhibidores de alk2 para el tratamiento de la anemia. | |
| MX2023004156A (es) | Terapia combinada para el tratamiento del cancer. | |
| AR122059A1 (es) | Usos y formulaciones de cannabinoides | |
| MX2025010161A (es) | Conjugados de anticuerpo-farmaco que comprenden derivados de trabectedina y lurbinectedina | |
| MX2024003258A (es) | Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. | |
| CL2024000208A1 (es) | Gedatolisib y sus combinaciones para usarse en el tratamiento de cáncer | |
| CL2021001830A1 (es) | Inhibidores de lta4h para el tratamiento de la hidradenitis supurativa | |
| MX2025006279A (es) | Tratamientos contra el cancer mediante un inhibidor de prmt5 y un inhibidor de mat2a | |
| MX2025015101A (es) | Un metodo para el tratamiento de tumores solidos con un conjugado anticuerpo-farmaco dirigido a claudina 18.2 | |
| MX2024010392A (es) | Remibrutinib para el uso en el tratamiento de hidradenitis supurativa. | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| AR128566A1 (es) | Combinaciones de fármacos y métodos para tratar el cáncer de ovario | |
| MX2023013514A (es) | Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga. | |
| UY39593A (es) | Tratamiento para tumores sólidos malignos | |
| ECSP22048726A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| PE20230181A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
| AR122344A1 (es) | Uso de reboxetina para tratar desórdenes del sistema nervioso | |
| MX2025001055A (es) | Terapias de combinacion para el tratamiento del cancer |